Who we are


We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on our proprietary technological platform DOS47.
Image

Our technology


DOS47 is our patented oncology platform technology that offers a new and revolutionary approach to the debilitation and destruction of cancer cells by modulating the tumor microenvironment.
learn more
Image

Patented

Patented oncology platform technology to destroy cancer cells
Image

Targeted

Designed to induce an increase in pH locally at the site of cancerous cells
Image

Dual Action

Combat tumor acidity and restore immunity

Latest news

All News